South Korean OK for BASF's Scottish Omega-3 plant

South Korean OK for BASF's Scottish Omega-3 plant

Related tags Omega-3 fatty acids Omega-3 fatty acid Fatty acid Nutrition

South Korean regulators have cleared BASF to produce pharmaceutical grade omega-3 at its facility in Scotland.

The approval follows a Korean Food and Drug Administration (KFDA) inspection of the German chemical giant’s BASF Pharma Callanish omega-3 unit on the Isle of Lewis and increases its presence in a key market according to spokesman Andres-Christian Orthofer.

He told in-Pharmatechnologist.com that: “South Korea has an interesting omega-3 drug market both in terms of volume and value and we see opportunities to further grow the market with new omega-3 drug products.”

BASF already has ‘significant’ pharmaceutical-grade omega-3 sales in the country according to Orthofer continued, explaining that this was largely due to its recent acquisition, Norway-based manufacturer Pronova Biopharma​.

One of the things that makes South Korea such an interesting market for BASF is 2012 legislation recommending that Koreans consume at least 2 grams of omega-3 fatty acids per day​ as part of a healthy diet, which is roughly eight times the minimum daily amount advised in Europe.

Omega-3 Pharma growth

The South Korean approval is part of a wider BASF effort to grow its pharmaceutical omega-3 fatty acid business globally that began with its purchase of Equateq and the Callanish facility in May last year.

Alan Poon, Head of BASF Pharma Ingredients & Services in Asia Pacific said: “We expect approvals in other Asian markets to follow, as we broaden our offering of omega-3 concentrates for the pharmaceutical sector even further.”

Orthofer echoed this, explaining that: “The market for omega-3 based drugs is relatively young with only a few drugs approved in a few countries.

Therefore, there are many opportunities globally to obtain regulatory approvals for existing omega-3 drugs and for future products​.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars